Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
08 2019
Historique:
received: 20 03 2019
revised: 26 05 2019
accepted: 28 05 2019
pubmed: 14 6 2019
medline: 15 10 2019
entrez: 14 6 2019
Statut: ppublish

Résumé

About 30% of Adult type granulosa cell tumors of the ovary (AGCTs) are diagnosed in fertile age. In stage I, conservative surgery (fertility-sparing surgery, FSS), either unilateral salpingo-oophorectomy (USO) or cystectomy are possible options. The aim of this study is to compare oncological outcomes of FSS and radical surgery (RS) in apparently stage I AGCTs treated within the MITO group (Multicenter Italian Trials in Ovarian cancer). Survival curves were calculated using the Kaplan-Meier method and compared with log-rank test. The role of clinicopathological variables as prognostic factors for survival was assessed using Cox's regression. Two-hundred and twenty-nine patients were included; 32.6% received FSS, 67.4% RS. In the FSS group, 62.8% underwent USO, 16.7% cystectomy, 20.5% cystectomy followed by USO. After a median follow up of 84 months, median DFS was significantly worse in the FSS-group (10 yr DFS 50% vs 74%, in FSS and RS group, p = 0.006). No significant difference was detected between RS and USO (10 yr DFS 75% vs 70%, p = 0.5).Cystectomy-group showed a significantly worse DFS compared to USO (10 yr DFS 16% vs 70%, p < 0.001). Patients receiving cystectomy and subsequent USO showed a better prognosis, even though significantly worse compared to USO (10 yr DFS 41% vs 70%, p = 0.05). Between FSS and RS, no difference in OS was detected. At multivariate analysis, FIGO stage IC and cystectomy retained significant predictive value for worse survival. This study supports the oncological safety of FSS in stage I AGCTs, provided that cystectomy is avoided; USO should be the preferred approach.

Identifiants

pubmed: 31189500
pii: S0090-8258(19)31273-9
doi: 10.1016/j.ygyno.2019.05.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-327

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

A Bergamini (A)

Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: bergamini.alice@hsr.it.

G Cormio (G)

Gynecologic Oncology Unit, Istituto Oncologico Giovanni Paolo II, Italy; University of Bari, Italy.

G Ferrandina (G)

Gynecologic Oncology Unit, Department of Woman, Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

D Lorusso (D)

Gynecologic Oncology Unit, Department of Woman, Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

G Giorda (G)

Gynecological Oncology Unit, Centro di Riferimento Oncologico - National Cancer Institute, Aviano, Italy.

G Scarfone (G)

Department of Obstetrics, Gynecology and Neonatology, IRCCS Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.

L Bocciolone (L)

Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy.

F Raspagliesi (F)

Gynecologic Oncology Unit, IRCCS National Cancer Institute Foundation, Milan, Italy.

S Tateo (S)

Unità Operativa di Ginecologia e Ostetricia, Ospedale "S. Chiara", Azienda provinciale per i servizi sanitari, Trento, Italy.

C Cassani (C)

Department of Obstetrics and Gynaecology Fondazione IRCCS Policlinico San Matteo-University of Pavia, Pavia, Italy.

A Savarese (A)

Division of Medical Oncology 1, Regina Elena Cancer Institute, Rome, Italy.

E Breda (E)

Medical Oncology Unit Ospedale S Giovanni Calibita Fatebenefratelli, Rome, Italy.

U De Giorgi (U)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.

F Mascilini (F)

Gynecologic Oncology Unit, Department of Woman, Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

M Candiani (M)

Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy.

A Kardhashi (A)

Gynecologic Oncology Unit, Istituto Oncologico Giovanni Paolo II, Italy.

N Biglia (N)

Obstetrics and Gynaecology Unit, Umberto I Hospital, Department of Surgical Sciences, School of Medicine, University of Turin, Turin, Italy.

A M Perrone (AM)

Department of Gynecology Oncology, Institute of Obstetrics and Gynecology, S. Orsola Hospital, Bologna, Italy.

S Pignata (S)

Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.

G Mangili (G)

Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH